2026-10-25
Does not pass
Allogene Therapeutics, does not pass the ethical screen. The binding factor is interest/revenue 91604.5%.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
Allogene Therapeutics, Inc.
ALLO · Nasdaq · USD · Market cap $449M · 150 employees
Allogene Therapeutics, Inc.
FAIL · Does not pass the screen1.04 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.04 USD at the 6 Nov 2026 close
- Our regime readDistribution, as of 7 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.00)
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-06).
- Trend Distribution
- Insiders insiders sold, $48,698, latest filing 2026-10-21
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.00, read 2026-11-02
- Ethical does not pass the values gate
Price1.04 USD
Ethical score83.9/100
Our investment reviews on this name
2026-09-21Read Markdown1.97-47.2% to today ✓Accumulation gives way to Markdown after a 12% slide in 4 weeks
2026-08-21Read Accumulation2.23-53.4% to today Markdown gives way to Accumulation after a 19% rise in 7 weeks
2026-07-02Read Markdown1.88-44.7% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Allogene Therapeutics, Inc. holds its Distribution at $1.04. The statistical read favours the sellers, held for 31 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 31 days |
| Price at the screen | $1.04 |
| Valuation | N/A trailing · -2.11 forward price to earnings |
| Values screen | FAIL · score 83.9 |
| Beta | 0.56 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 91604.5%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.63% | Below 33% | Interest-bearing debt is just 10.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 31.95% | Below 33% | Cash held in interest-bearing accounts and securities is 31.9% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 91,604.55% | Below 5% | 91,604.5% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Allogene Therapeutics, does not pass the ethical screen. The binding factor is interest/revenue 91604.5%.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Allogene Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 11%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when ALLO's ethical verdict changes
Today ALLO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets. The average target sits +765% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -2.1x |
| EPS, trailing | -0.66 |
| EPS, forward | -0.62 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -42.4%not currently earning a positive return on equity |
| FCF yield | -14.13% |
| Debt to equity | 0.18minimal debt: a conservative balance sheet |
| Current ratio | 10.72comfortably covers its short-term bills |
| Beta | 0.56steadier than the market |
| Short interest, float | 0.18% |
| 52-week range | 1.04 - 4.46 |
| Market cap | $449M |
| Employees | 150 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeALLO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-02
Markdown $1.18
-11.9% Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-10-26
Markdown $1.34
+0.0% Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-10-19
Markdown $1.34
-8.2% Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-10-12
Markdown $1.46
-12.6% Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-10-02
Markdown $1.67
-15.2% Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-09-21
Markdown · changed $1.97
-11.7% Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-08-21
Accumulation · changed $2.23
+24.6% Entry 6
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 24.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-07-21
Markdown $1.79
-4.8% Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-07-18
Markdown $1.88
+0.0% Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
2026-07-17
Markdown $1.88
+0.0% Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 26% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (11 analysts) rates it strong buy, with a mean price target of $8.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot Stocktwits · 15 Sep 2026
- CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot Yahoo Finance · 15 Sep 2026
- Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Zacks · 11 Sep 2026
- Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Yahoo Finance · 11 Sep 2026
- Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts BioPharma Dive · 2 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
HELPHelus Pharma Inc
KYTXKyverna Therapeutics Inc
PRTAProthena Corp Plc
RZLTRezolute Inc
OVIDOvid Therapeutics Inc
EDITEditas Medicine Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Parker Geoffrey M. | CFO | S - Sale | 36,342 | $48,698 |
| 2026-04-21 | YOSHIYAMA ANNIE | Officer | 9,586 | $22,144 | |
| 2026-03-31 | BENESKI BENJAMIN MACHINAS | Chief Technology Officer | 2,867 | $7,168 | |
| 2026-03-16 | CHANG DAVID D | Chief Executive Officer | 47,763 | $117,975 | |
| 2026-03-16 | BENESKI BENJAMIN MACHINAS | Chief Technology Officer | 4,835 | $11,942 | |
| 2026-03-02 | BENESKI BENJAMIN MACHINAS | Chief Technology Officer | 7,132 | $18,543 | |
| 2026-02-02 | DOUGLAS EARL MARTIN | General Counsel | 22,900 | $40,304 | |
| 2026-02-02 | CHANG DAVID D | Chief Executive Officer | 95,269 | $171,484 | |
| 2026-02-02 | PARKER GEOFFREY M | Chief Financial Officer | 24,001 | $42,242 | |
| 2026-02-02 | YOSHIYAMA ANNIE | Officer | 4,167 | $7,167 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-25 | Michael McCaul | Republican | buy | 50K–100K |
| 2026-08-25 | Michael McCaul | Republican | buy | 50K–100K |
| 2026-08-25 | Michael McCaul | Republican | buy | 50K–100K |
| 2026-08-19 | Michael McCaul | Republican | buy | 1K–15K |
| 2026-08-19 | Michael McCaul | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $2.28 | -21.3% | · | $787 | -21.3% |
| 2 months | $2.72 | -34.0% | · | $660 | -34.0% |
| 3 months | $2.47 | -27.3% | · | $727 | -27.3% |
| 6 months | $1.55 | +15.8% | · | $1,158 | +15.8% |
| 1 year | $1.46 | +23.0% | · | $1,230 | +23.0% |
| 2 years | $2.44 | -26.4% | · | $736 | -26.4% |
| 3 years | $5.64 | -68.2% | · | $318 | -68.2% |
| 5 years | $26.10 | -93.1% | · | $69 | -93.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever ALLO does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.